scholarly journals Antibodies to pituitary surface antigens during various pituitary disease states

2002 ◽  
Vol 175 (2) ◽  
pp. 417-423 ◽  
Author(s):  
YM Keda ◽  
IV Krjukova ◽  
IA Ilovaiskaia ◽  
MS Morozova ◽  
OV Fofanova ◽  
...  

Autoantibodies to cell surface antigens of human somatotropinoma (ASAS), human prolactinoma (ASAP) and rat adenohypophysis (ASARA) were assayed in the serum of patients with pituitary diseases associated with GH deficiency (GHD), such as pituitary dwarfism and primary empty sella syndrome (ESS), and in the serum of patients with hyperprolactinaemia of different etiologies: idiopathic hyperprolactinaemia, prolactinoma and ESS. The investigation was carried out with a cellular variant of an ELISA. Among children with GHD, the highest percentage of antibody-positive patients was found in the group with idiopathic isolated GHD (89% of ASAS(+) patients and 30% of ASARA(+) patients vs 33.3% and 0% respectively in the group with idiopathic combined pituitary hormone deficiency, and 33.3% and 9% in patients with pituitary hypoplasia associated with isolated GHD or combined pituitary hormone deficiency). Among hyperprolactinaemic patients, the highest ASAP and ASARA frequency was observed in patients with idiopathic hyperprolactinaemia (67.7% and 41.9% respectively) where it was twice as high as in the group of patients with prolactinoma. The proportion of ASAS(+) and ASARA(+) did not differ significantly between the groups of patients with ess with or without GHD. Similarly, there was no significant difference between the number of ESS ASAP(+) and ASARA(+) patients with or without hyperprolactinaemia. The data obtained suggested that autoimmune disorders may be primary, and responsible, at least in part, for pituitary dysfunction in the cases of idiopathic isolated GHD and idiopathic hyperprolactinaemia. At the same time, the autoimmune disorders in the patients with prolactinoma or ESS are probably secondary to the organic pituitary lesion and their significance in the development of the pituitary dysfunction is obscure.

Author(s):  
Damian Rogoziński ◽  
Aleksandra Gilis-Januszewska ◽  
Łukasz Kluczyński ◽  
Magdalena Godlewska ◽  
Alicja Hubalewska-Dydejczyk

2016 ◽  
Vol 174 (6) ◽  
pp. R239-R247 ◽  
Author(s):  
Frederic Castinetti ◽  
Rachel Reynaud ◽  
Alexandru Saveanu ◽  
Nicolas Jullien ◽  
Marie Helene Quentien ◽  
...  

Over the last 5 years, new actors involved in the pathogenesis of combined pituitary hormone deficiency in humans have been reported: they included a member of the immunoglobulin superfamily glycoprotein and ciliary G protein-coupled receptors, as well as new transcription factors and signalling molecules. New modes of inheritance for alterations of genes encoding transcription factors have also been described. Finally, actors known to be involved in a very specific phenotype (hypogonadotroph hypogonadism for instance) have been identified in a wider range of phenotypes. These data thus suggest that new mechanisms could explain the low rate of aetiological identification in this heterogeneous group of diseases. Taking into account the fact that several reviews have been published in recent years on classical aetiologies of CPHD such as mutations ofPOU1F1orPROP1, we focused the present overview on the data published in the last 5 years, to provide the reader with an updated review on this rapidly evolving field of knowledge.


2017 ◽  
Vol 62 (8) ◽  
pp. 755-762 ◽  
Author(s):  
Eleonore Bertko ◽  
Jürgen Klammt ◽  
Petra Dusatkova ◽  
Mithat Bahceci ◽  
Nazli Gonc ◽  
...  

10.1038/76041 ◽  
2000 ◽  
Vol 25 (2) ◽  
pp. 182-186 ◽  
Author(s):  
Irène Netchine ◽  
Marie-Laure Sobrier ◽  
Heiko Krude ◽  
Dirk Schnabel ◽  
Mohamed Maghnie ◽  
...  

2011 ◽  
pp. P1-266-P1-266
Author(s):  
Debora Cristina Moraes ◽  
Karina Schiavoni Scandelai Cardoso dos Reis ◽  
Gisele Dazzi Lorenzoni ◽  
Flavia Lucia Conceicao ◽  
Mario Vaismann ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document